The P-II study assessed frexalimab in relapsing MS patients administered with either high dose (1200mg, IV, Q4W with 1800mg loading dose) or low dose (300mg, SC, Q2W with 600mg loading dose) vs matching PBO for 12wks. (part A). P-III trials for relapsing MS & non-relapsing secondary progressive MS has initiated recruitment
In the study, 97% of them from 12wk. treatment proceeded to OLE P-II study with 87% remaining by the 48wk. Results showed reduced plasma NfL levels by 41% (high-dose) & 35% (low-dose) from baseline to wk.48
Moreover, patients had 24% (switched to high dose) & 33% (switched to low dose) reduced plasma NfL levels at wk.12 from baseline to wk.48 with 39% after wk.12 in both
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
